EMSAM

LOE Approaching

selegiline

NDATRANSDERMALSYSTEM
Approved
Feb 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1

Mechanism of Action

(the drug substance of EMSAM) as an antidepressant is not fully understood, but is presumed to be linked to potentiation of monoamine neurotransmitter activity in the central nervous system (CNS) resulting from its irreversible inhibition of the enzyme monoamine oxidase (MAO).

Indications (1)

major depressive disorder (MDD) ()

Clinical Trials (1)

NCT00443872Phase 4Completed

Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists

Started Mar 2007
77 enrolled
Parkinson's Disease
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers